Week of March 25, 2019 | Vol. 8, Issue 12
In This Issue
Featured Headlines
Recent Industry Transactions
Industry Trading Comps
Recent Industry Headlines
Market Reports
Upcoming Events

Quick Links

Contact Information
Managing Director
Business Development

Managing Director
Head of M&A and Capital Advisory

Above is an overview of recent industry M&A activity. For additional information, see the charts below or click on the chart above to download complete transaction tables broken out by industry sub sectors.
Fluid-based lensmaker PowerVision acquired by Alcon for $285M

2016 Fierce 15 company PowerVision is being picked up by Novartis’ heavyweight eye-care unit Alcon .
2016 Fierce 15 company PowerVision is being picked up by Novartis’ heavyweight eye-care unit Alcon, in a $285 million deal for its innovative, fluid-based intraocular lens implant for people with cataracts. Alcon first acquired an option to buy PowerVision  in early 2016 , calling its technology a potential game-changer, and signed on to a partnership adjacent to the Belmont, California-based company’s $40 million series D round. Going forward, Alcon says its goals to sell the shape-changing implant worldwide will depend on “significant additional development and clinical trials of the intraocular lens” over the coming years, with the company committing to additional milestone payments that won’t begin until 2023. “As the industry leader in cataract surgery, we’re eager to accelerate development of this potentially breakthrough accommodating lens technology,” Alcon’s President of Global Business and Innovation Michael Onuscheck said in a  statement .

 C ontinue Reading at Fierce Biotech
An Overview of Transactions Within Market Sub-segments
Below are summaries and charts with the past week's transactions from the different healthcare sectors. For a detailed table showing data for each industry transaction click on any of the charts. Total transaction values are provided in USD millions.
Pharma & Biotech
17 transactions totaling $287 million
Supplies, Equipment & Services
17 transactions totaling $297 million
Healthcare IT & Managed Care
5 transactions
Healthcare Facilities & Distributors
9 transactions totaling $254 million
Pharma & Biotech
29 transactions totaling $642 million
Supplies, Equipment & Services
14 transactions totaling $71 million
Healthcare IT & Managed Care
7 transactions totaling $25 million
Healthcare Facilities & Distributors
1 transaction
Pharma & Biotech
23 transactions totaling $852 million
Supplies, Equipment & Services
7 transactions totaling $213 million
Healthcare IT & Managed Care
2 transaction totaling $74 million
Healthcare Facilities & Distributors
0 transactions
A Breakdown of Relevant Trading Multiples
Each week, we provide updated trading comps for leading companies from numerous healthcare sub-sectors.
To the right you will see a high-level breakdown of median revenue and EBITDA multiples for each of the specific sub sectors.

For a complete trading comp analysis (including the individual equities that comprise the sub sectors), click on the table. 

Note: data reflects prior week close.
A Sampling of Relevant Industry Headlines from Last Week
Below are snippets from relevant industry news articles from the past week. For additional information or the article's complete text, click the headline link to view the original publication.
March 22, 2019 - Bio Space
Johnson & Johnson  has taken a  $900 million hit  as it writes off an investigational treatment for Respiratory Syncytial Virus (RSV) and human metapneumovirus the company acquired in its  2014 $1.7 billion deal for Alios BioPharma .

March 21, 2019 -  Fierce Biotech
Alexion and Zealand Pharma have  teamed up  to develop peptide therapies for complement-mediated diseases. The deal will see Alexion pay $25 million (€22 million) upfront to work with Zealand on the subcutaneously delivered therapies.

March 20, 2019 -  Fierce Biotech
Vivet is in the crosshairs of Big Pharma Pfizer as the U.S. giant looks to get in on the new industry craze of buying up small gene therapy biotechs.

March 19, 2019 -  Reuters
Columbia Pacific Management’s Asian hospital business has drawn interest from global private equity players including KKR, CVC and Carlyle, in a sale the U.S. investment company sees fetching about $2 billion, sources with knowledge of the matter said.

March 19, 2019 - BioPharma Dive
Nightstar is the third gene therapy-focused biotech to be acquired by a larger drugmaker since the landmark approval in late 2017 of Spark Therapeutics'​ Luxturna (voertigene neparvovec) — the first gene therapy for an inherited disease to be OK'd in the U.S.
Recent Materials Providing Insight Into Healthcare Related Industries
March 2019